TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT03736018

Intervention type: DIAGNOSTIC_TEST
Group type: ACTIVE_COMPARATOR
Intervention: CTCA
Description: Computed Tomography Cardiac angiography (CTCA) performed prior to invasive coronary angiogram (ICA).
Study: NCT02323009

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Esophageal Balloon
Description: Esophageal balloon was used to measure esophageal pressure (Paux) which was used as an estimate of pleural pressure. Transpulmonary pressure (Ptp) was calculated as the difference between airway pressure (Pao) and Paux. Applied PEEP was then adjusted to overcome negative Ptp which we maintained between 0 to 10 cm H20. All measurements were made at end-expiration.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Cstat
Description: PEEP was adjusted to achieve the best CStat in this group of patients
Study: NCT02674503

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Walking
Description: MP patients will participate in a program of progressive walking and transfer training up to three times a day, seven days a week throughout the hospital stay. MP patients will begin with assisted sitting, then standing, progressing to weight shifting and stepping in place, and then to walking as tolerated. The level of mobility recommended to the MP patient by the Walker will be dependent on the individual patient and will incorporate the activities patients were deemed able to do independent of cueing or assistance during each walking session.

Intervention type: BEHAVIORAL
Group type: PLACEBO_COMPARATOR
Intervention: Friendly visit
Description: UC patients will receive three times a day friendly visits, seven days a week by members of the research team to control for the daily attention that MP patients receive.
Study: NCT02019355

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: 5-fluorouracil 5% cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-fluorouracil 5% cream

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Calcipotriol 0.005% ointment

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Vaseline
Study: NCT00903201

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB656933
Description: 20 mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: SB656933
Description: 50mg

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Placebo
Description: placebo
Study: NCT01212510

Intervention type: OTHER
Group type: OTHER
Intervention: Blood sampling
Description: blood rate of ACE, CA19-9, circulating tumor cell, circulating tumor DNA
Study: NCT04571489

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Gimatecan
Description: Patients will receive gimatecan orally at 0.8mg/m2 on day 1-5 every 4 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: tegafur, gimeracil and oteracil potassium
Description: Patients will receive tegafur, gimeracil and oteracil potassium orally at 40 or 60mg twice daily on days 1 to 14 every 3 weeks.

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: gemcitabine
Description: Patients will receive gemcitabine IV at 1000mg/m2 on days 1、8 every 3 weeks.
Study: NCT03823157

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Tai Chi
Description: mind-body exercise
Study: NCT04370496

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Minimally invasive surgery using endoscopic stapler
Description: Radical hysterectomy by minimally invasive surgery (laparoscopic or robotic) will be done with the help of an endoscopic stapler in cutting and suturing the uterine cervix.
Study: NCT02664688

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Lumbar stabilization exercises
Description: The home-exercise program included an initial phase, with use of therapeutic heat via a hot pack for 15 minutes at the lumbosacral region, stretching exercises of the thoracolumbar fascia, hip flexors, hamstrings plus the stabilization exercises to encourage stabilizing motor patterns and determine the neutral position of the spine, with the target in control of transversus and internal oblique abdominis, multifidus, pelvic floor muscles, and diaphragmatic breathing control. Progression stages included hot packs, stretching exercises, and lateral, anterior bridges, leg raises in supine position, and arm and leg lifts in quadruped position (bird-dog)

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Flexor exercises
Description: The home-exercise program included a hot pack for 15 minutes and flexor exercises routine
Study: NCT01933724

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5 mg prednisone
Description: Subjects will be randomized to take 5 mg per day of prednisone for a 6 month period.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 0 mg prednisone
Description: Subjects will be randomized to taper their prednisone dose to no prednisone for a 6 month period.
Study: NCT01446705

Intervention type: OTHER
Intervention: Active Health Information Exchange
Description: Patients selected to share data between the VA \& external healthcare agencies.

Intervention type: OTHER
Intervention: Non-Active Health Information exchange
Description: Patients not selecting to share data
Study: NCT02934178

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei Strain WRSS1 Vaccine
Description: Live attenuated, oral Shigella WRSS1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei Strain WRSS1 Vaccine
Description: Live attenuated, oral Shigella WRSS1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei Strain WRSS1 Vaccine
Description: Live attenuated, oral Shigella WRSS1 vaccine

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Shigella sonnei Strain WRSS1 Vaccine
Description: Live attenuated, oral Shigella WRSS1 vaccine

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline solution

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Sterile saline solution
Study: NCT00557466

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: indacaterol
Description: Indacaterol delivered by multiple dose dry powder inhaler (TWISTHALER® device).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: formoterol
Description: Formoterol delivered by oral inhalation via AEROLIZER® inhalation device.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: placebo to indacaterol
Description: Placebo TWISTHALER® device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to indacaterol
Description: Placebo TWISTHALER® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: placebo to formoterol
Description: Placebo AEROLIZER® device

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short acting β2- agonist
Description: 100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: short acting β2- agonist
Description: 100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short acting β2- agonist
Description: 100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short acting β2- agonist
Description: 100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: short acting β2- agonist
Description: 100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: short acting β2- agonist
Description: 100 μg / 90 μg salbutamol/albuterol Metered Dose Inhaler (MDI) or equivalent dose of Dry Powder Inhaler (DPI).
Study: NCT02349438

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: senofilcon A
Description: A soft spherical contact lens

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: senofilcon A
Description: A soft spherical contact lens

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: lotrafilcon B

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: lotrafilcon B
Study: NCT01949545

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered by IV injection over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered by IV injection over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered by IV injection over 30 minutes

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Carfilzomib
Description: Carfilzomib was administered by IV injection over 30 minutes
Study: NCT00532623

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Gemcitabine plus Vinorelbine
Description: Gemcitabine, 1,000mg/m2 and Vinorelbine, 25mg/m2, on day 1 and day 8, every 3 week cycles

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Sequential
Description: Gemcitabine monotherapy followed by Vinorelbine monotherapy:~-Gemcitabine: 1,200 mg/m2, intravenously, on day 1 and day 8 in 3 week cycles. Vinorelbine: 30 mg/ m2, intravenously, on day 1 and day 8 in 3 week cycles.
Study: NCT04198168

Intervention type: DRUG
Intervention: IV crystalloid fluid bolus
Description: The participant receives IV fluid as a standardised bolus of 7 ml/kg (ideal body weight).
Study: NCT00408499

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: cetuximab
Description: Cetuximab will be administered intravenously weekly at the maximum tolerated dose (determined in Phase I portion of the study) on a 28 day cycle. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: erlotinib
Description: Erlotinib will be taken by mouth daily on a 28 day cycle. It is in tablet form. The dose will be determined in Phase I portion of the study. Participants will be in this study for at least 2 cycles (8 weeks). If the evaluations show that this treatment has been effective against the participant's cancer, he/she will continue the therapy.
Study: NCT03957993

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Occupational Therapy via Telehealth
Description: The caregiver will be with the participant in their home environment receiving occupational therapy via Telehealth (video-calling) with the occupational therapist.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Standard of Care Occupational Therapy
Description: The caregiver and participant will be in the clinic receiving occupational therapy in-person with the occupational therapist.
Study: NCT00668616

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cyclophosphamide, Epirubicin, Paclitaxel
Description: 4 cycles of 600 mg/m² cyclophosphamide i.v. and 90 mg/m2 Farmorubicin i.v. on day 1, q21d followed by 4 cycles of 175 mg/m² Taxol, day 1, q21d

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Epirubicin, Paclitaxel, Filgrastim
Description: cycle 1-4: 120 mg/m² Epirubicin i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl) cycle 5-8: 175 mg/m² Paclitaxel i.v. on day 1, q14d, 5 µg/kg s.c. filgrastim day 5-10 (if leucocytes are lower than 10000/µl)
Study: NCT04113603

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinary malignancy
Description: Single bolus three phase CTU

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Urinary malignancy
Description: Single bolus three phase CTU
Study: NCT04168957

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Oraxol
Description: Oraxol (oral paclitaxel + oral HM30181AK-US)~Paclitaxel: supplied as capsules HM30181 methanesulfonate monohydrate: supplied as HM30181AK-US tablets
Study: NCT03355144

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: Daily Supplementation with Coffee
Description: At the beginning of study week 2 (study day 8), two coffee machines (one Nespresso Inissia and one Hamilton Beach 46205 12 Cup Programmable Coffee Maker) will be installed in the resident work rooms at each site.~Subjects will be provided with free coffee beans, milk, cream, sugar and sweetener
Study: NCT04546763

Intervention type: DEVICE
Intervention: Study Watch
Description: The Study Watch is a miniaturized wearable device made with biocompatible contact materials containing various sensors capable of measuring physiological and environmental metrics.

Intervention type: DEVICE
Intervention: Zio XT
Description: The Zio XT Patch, the reference device, is a FDA-cleared single-patient use, continuously recording ECG monitor that can be worn up to 14 days.
Study: NCT02549118

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Tenoxicam

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Pethidine
Study: NCT01408472

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: NT-501 CNTF Implant
Description: Single implantation of CNTF-secreting NT-501 device into one eye
Study: NCT01898416

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: 5-AMINOLEVULINIC ACID (5-ALA), is a non fluorescent prodrug.
Description: 60 mg/kg 5-ALA prepared solution given orally, 3-5 hours before induction of anesthesia.~Red light laser given by a Dye laser system, wave length of 635nm, in s dose of 150J/cm for 2000 seconds (33 minutes) will be given to tumor bed. In case of positive margins a second operation and 5-ALA administration or irradiation will be given.
Study: NCT01648764

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2334737
Description: Administered orally

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: LY2334737
Description: Administered orally
Study: NCT01262586

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Vildagliptin

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Glimepiride
Study: NCT04542941

Intervention type: BIOLOGICAL
Group type: ACTIVE_COMPARATOR
Intervention: COVID Convalescent Plasma
Description: Plasma collected from recovered COVID 19 individuals
Study: NCT04023968

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: YESplus workshop
Description: See description in Arms section.

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: WOW! workshop
Description: See description in Arms section.
Study: NCT03031925

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: ANXA2
Description: serum and urinary concentration

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: ANXA2
Description: serum and urinary concentration
Study: NCT02950389

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMMA filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: PMMA filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFR17 filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: HFR17 filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F7 filter

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: F7 filter
Study: NCT02305316

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 non-micronized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 non-micronized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 micronized

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: BIA 9-1067 micronized
Study: NCT00903968

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Plerixafor

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: bortezomib

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Dexamethasone
Study: NCT03176914

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: prevention and management of childhood illnesses at community level
Description: provision of critical health education and targeted promotion services to the participants in their locality

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: conventional community interventions
Description: community health programs as the sole source of health education
Study: NCT00843349

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Phosphorus binder

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Lanthanum Carbonate
Description: Phosphorus binder

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 900 mg Phosphate Diet
Description: Amount of phosphorus consumption in a day kept below 900 mg.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: 900 mg Phosphate Diet
Description: Amount of phosphorus consumption in a day kept below 900 mg.

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: LC Placebo
Description: Placebo for Lanthanum Carbonate

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: LC Placebo
Description: Placebo for Lanthanum Carbonate

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Ad Libitum Diet
Description: Patients continued to eat their usual diet.

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Ad Libitum Diet
Description: Patients continued to eat their usual diet.
Study: NCT00980876

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Cipro HC
Description: Cipro HC (Ciprofloxacin HCl and Hydrocortisone)

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ciprofloxacin HCl and Hydrocortisone
Description: Ciprofloxacin Hydrochloride and Hydrocortisone
Study: NCT02120404

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol administration
Description: Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.~Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.~The titrated dose will be maintained for a total duration of 24 hours.

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Esmolol administration
Description: Esmolol will be administered during 24 hours, beginning with a titration period to determine the minimal dose allowing to achieve the randomized heart rate reduction of 10% or 20%, as defined by randomization.~Titration will be performed in sequences of increasing doses, beginning with 5 μg/kg/min as initial dose, and increasing by 5 μg/kg/min each 30 minutes until the target heart rate reduction is obtained. The maximum dose is 200 μg/kg/min.~The titrated dose will be maintained for a total duration of 24 hours.
Study: NCT00089648

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Sunitinib
Description: 50 mg orally daily for 4 weeks followed by 2 weeks off treatment for approximately 1 year or until disease progression/unacceptable toxicity; after completion of 1 year, pts with clinical benefit can continue the study treatment in a separate continuation protocol
Study: NCT01454752

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Intermittent parasite clearance
Description: Sulphadoxine-pyrimethamine (500/25mg) according to age, given on day 1; Amodiaquine (200mg) according to age, given daily for 3 days

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo tablets, similar in appearance and taste to active treatment, given daily over 3 days
Study: NCT03515408

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: rTMS
Description: The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: rTMS
Description: The 10-Hz stimulation is delivered at 100% of the subject's resting motor threshold via 60 trains of 3-s 10-Hz rTMS (30 pulses with 27-s duration per train).
Study: NCT00420745

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Rotarix™
Description: Two-dose oral vaccination.

Intervention type: BIOLOGICAL
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Two-dose oral administration